Curetopia

Summary

There are 10,000 rare diseases with an average market size of $150M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed biotech, with a single indication or platform. This makes the current market approach incapable of going after one of the thousands of $150M rare disease markets. However, these $150M markets are exactly where Curetopia shines and has a competitive moat.

Problem

There are 10,000 rare diseases with an average market size of $150M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed biotech, with a single indication or platform. This makes the current market approach incapable of going after one of the thousands of $150M rare disease markets. However, these $150M markets are exactly where Curetopia shines and has a competitive moat.

Impact

There are 10,000 rare diseases with an average market size of $150M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed biotech, with a single indication or platform. This makes the current market approach incapable of going after one of the thousands of $150M rare disease markets. However, these $150M markets are exactly where Curetopia shines and has a competitive moat.